May 2026
📣 VC round data is live. Check it out!
Largest Contract Research & Manufacturing Public Companies in India
Benchmark revenue and EBITDA valuation multiples for public comps like
Divi's Laboratories, Laurus Labs, Dixon Technologies, Sai Life Sciences and Piramal Pharma.
 | Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world. | $71 | -1% | $19B | $18B | 16.7x | 45.4x | ||
| Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others. | $14 | +115% | $8B | $8B | 13.7x | 67.3x | ||
| Dixon Technologies (India) Ltd provides electronic manufacturing services (EMS) to its customers, serving as an original equipment manufacturer (OEM) as well as an original design manufacturer (ODM) for various brands. It is engaged in the in manufacturing of electronic goods such as consumer durables, home appliances, lighting products and mobile phones. It operates in single operating segment: Electronics Goods. The company engages in domestic sales of goods as well as exports its products outside India, of which a majority of its revenue is generated from the domestic market. | $124 | -22% | $7B | $7B | 1.4x | 27.0x | ||
| Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India. | $12 | +50% | $3B | $3B | 11.4x | 37.1x | ||
| Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets. | $2 | -16% | $2B | $3B | 3.1x | 28.1x | ||
| Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India. | $8 | +38% | $2B | $2B | 3.6x | 16.2x | ||
| Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others. | $5 | -31% | $2B | $2B | 4.7x | 18.4x | ||
| Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world. | $11 | -17% | $2B | $2B | 2.2x | 14.3x | ||
| Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO). | $5 | -12% | $833M | $671M | 1.5x | 10.2x | ||
| Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India. | $8 | -22% | $695M | $773M | 4.1x | 19.2x | ||
| Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences. | $14 | -- | $351M | $282M | 7.6x | 20.3x | ||
| Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India. | $2 | -28% | $327M | $541M | 1.8x | 8.4x | ||
| Median | $9 | -16% | $2B | $2B | 3.8x | 19.8x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.